Emily Leonard is the vice-chair of the firm’s Life Sciences Industry Group and a member of the corporate and intellectual property practice groups. She is resident in the firm’s Palo Alto office. Ms. Leonard concentrates in transactions for pharmaceutical and biotechnology clients, with an emphasis on complex strategic partnering and collaboration agreements, joint ventures, licensing and other technology transfer arrangements.
She also advises clients ranging from early-stage ventures to large public and private companies with respect to the full range of clinical and commercial agreements that span the life cycle of a drug product or medical device, including technology evaluation, sponsored research, clinical study, clinical research organization, professional services, manufacturing and co-promotion agreements.
Her early years at the firm also included experience in all facets of civil litigation, including second-chairing a three-week jury trial in which the jury returned a defense verdict for Covington’s client in a defamation case, as well as representation of white collar and other defendants in criminal investigations and proceedings.
- The George Washington University Law School, J.D., 1994
- Catholic University of America, B.A., 1990
Bar Admissions :
- District of Columbia
- New York
Representative Matters :
- Biosynexus in its reacquisition of rights to its lead antibody product for the treatment of staph infections in premature infants.
- Institute of OneWorld Health, a non-profit pharmaceutical company, in the negotiation of collaboration and other agreements for the advancement and commercialization of drug products for neglected diseases, particularly those that disproportionately affect developing world countries.
- Medarex in a strategic alliance with a Japanese pharmaceutical company, involving the cross license of platform technologies consisting of transgenic and transchromosomic mouse technologies, and in connection with a number of other collaboration agreements concerning antibody products.
- Novartis (formerly Chiron) in various transactions, including the divestiture of an epidermal delivery technology, and in the divestiture of certain patent families from its gene therapy portfolio.
- P&G (formerly Gillette) in a worldwide licensing arrangement involving the acquisition of rights to exploit the first light-based aesthetic device to receive a 510(k) over-the-counter clearance from FDA.
Rate : $$$$